drugset
drugset / Trial / NCT04134117

Tisagenlecleucel In Primary CNS Lymphoma

NCT04134117 ↗

Phase 1 Completed 13 enrolled Matthew J. Frigault, M.D. Novartis · collab
NaSingle-groupOpen-labelTreatment

Summary

In this study, is researching the safety of tisagenlecleucel in participants with primary central nervous system lymphoma. . -The name of the study intervention is tisagenlecleucel.

Timeline

Start
2019-01-01
Primary completion
2022-04-14
Completion
2022-04-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Tisagenlecleucel Cell therapy — Intravenous

Indications

primary central nervous system lymphoma